Biopharmaceutical Research Consortium Structure and Governance

CQDM operates through its representative bodies: the Board of Directors and its committees, officers, members and other representatives.

Board of Directors

The Board of Directors and its five sub-committees are largely responsible for the governance of the biopharmaceutical research consortium. Members of the Board meet four times per year and oversee the sound management of the biopharmaceutical research consortium. They ensure that financial matters are dealt with carefully and independently, in compliance with the selection criteria of each funding program maintained by CQDM.

Members of the Board of Directors represent all stakeholders of the biopharmaceutical research consortium and draw on their extensive experience to help CQDM maximize the impact of funded projects and reach its objectives.

Chairman

Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation

Observers

Yvon Fréchette
Innovation Advisor
Collaborative Research Department
Ministry of Economy and Innovation (MEI)

Secretary

François Painchaud 
Lawyer, Partner,
ROBIC, LLP

Members

Jennifer Chan
Vice President, Policy and External Affairs,
Merck Canada

Diane Gosselin
President and Chief Executive Officer,
CQDM

Daniel Hétu
Managing Director,
Lumira Ventures

Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Sarah Jenna
Co-founder and CEO,
My Intelligent Machines (MIMs)

Frédéric Ors
Biotech Executive

Ken Pastor
General Partner,
CTI Capital

Louise Proulx
Corporate Director

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

Rémi Quirion
Chief Scientist of Quebec

Uwe Schoenbeck
Senior VP & Chief Scientific Officer, External R&D Innovation,
Pfizer worldwide R&D

Philip Tagari
CSO, Insitro

Executive Committee

The Executive Committee meets regularly to settle specific aspects of the biopharmaceutical research consortium’s business activities.

Chairman

Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation

 

 

Members

Jennifer Chan
Vice President, Policy and External Affairs,
Merck Canada

Diane Gosselin
President and Chief Executive Officer,
CQDM

Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Ken Pastor
General Partner,
CTI Capital

Louise Proulx
Corporate Director

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

Audit Committee

The Audit Committee is a sub-committee of the Board that meets at least twice per year to review the financial statements and receive notification of any errors or misstatements contained in financial statements from the external auditors.

Chairman

Ken Pastor
General Partner,
CTI Capital

Members

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

Daniel Hétu
Managing Director,
Lumira Ventures

 

Corporate Governance and Nominating Committee

The Corporate Governance and Nominating Committee ensures that the best resources and members are supporting the structure and governance of the biopharmaceutical research consortium.
The Committee oversees the recruitment, resignation and replacement process of new Board members. Its ultimate goal is to help CQDM focus on executing its strategy, while leveraging the experience of the Board.

Chairman

Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation

 

 

Members

Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Diane Gosselin
President and Chief Executive Officer,
CQDM

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

Scientific Advisory Board

The Scientific Advisory Board was created by the Board of Directors and is comprised of experienced and independent scientists. The members examine all external scientific reviews obtained by CQDM, ensure that projects targeted for funding meet all selection criteria and present their recommendations to the Board of Directors. The Scientific Advisory Board is the reason why CQDM can testify that it maintains a stringent selection process that maximizes positive R&D impacts for its members.

Chairman

Brian Underdown
Biotechnology Consultant,
BJUConsulting

Observers

Catherine Richard
Advisor, Industrial Partnerships,
Quebec Ministry of Economy and Innovation (MEI)

Diane Gosselin
President and Chief Executive Officer,
CQDM

Members

David Bouffard
PMT (Personalize my Treatment) Director
Exactis Innovation

Christine Brideau
Vice President of In Vitro Pharmacology
Deerfield Discovery and Development, LLC

André Darveau
Executive Vice Rector and Vice Rector, Human Resources and Finance
Université Laval

Benjamin Haibe-Kains
Senior Scientist
Princess Margaret Cancer Centre – University Health Network

Mark Lim
Vice President | Research, Discovery, and Innovation
ASN Alliance for Kidney Health

Cameron Black
Executive Vice President Discovery
Repare Therapeutics

John Delaney
Biotechnology Sr. Advisor

Jennifer Hamilton
Life sciences consultant

Kuldeep Neote
Entrepreneur In Residence
National Institutes of Health & FACIT/OICR